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The mortality and morbidity of newborns with
low birth-weight are considerably higher than in
newborns with normal body-weight. The in-
cidence of perinatal death and injury is highest in
the low birth-weight group. In countries with
low prematurity rates perinatal mortality is in
most cases correspondingly low, e. g. Sweden
and the Netherlands.
Hence the most pressing task of obstetrical and
perinatal medicine is to lower the number of new-
borns with low birth-weight to the minimum.
PAPIERNIK [10] and our staflf [12] have developed
independently programs which can be used
for evaluating in advance the risk of low
birth-weight, so that appropriate measures can
be taken in time.
1. Development of our program
The program was started in 1971. We selected
pregnant women at risk using a list of 36 risk
factors. These factors were chosen on the basis
of published data and our own clinical experience
[2, 3, 5, 6, 7, 13, 15, 16].
They were separated into factor groups: non-
treatable factors or factors of persisting risk
after treatment (e. g. previous abortions or
uterine bleeding early in gestation) and treatable
or removable factors (e. g. smoking or de-
velopment of gestosis).
We also determined whether the presence of the
individual factor increases the risk of prematurity,
dysmaturity or both.
Since there were no exact data available on the re-
lative validity of each factor they were first
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registered in a PDP-list I [12], each factor having
equal validity. This was known to be unsatis-
factory but unavoidable if a Start was to be made.
The list was filled in during the first examination
of the pregnant woman at the clinic and sup-
plemented äs required during later visits.
If more than 2 risk factors indicated possible
premature labor or 2 or more factors possible
dysmaturity, the patient was given special
prenatal care, described in more detail below.
A year later we evaluated our material. One of the
first consequences was to change PDP-list I.
Instead of using factors of equal validity, each
factor was assigned a certain number of
points. This was an attempt to evaluate individual
factor more precisely. PDP-list II resulted from
this procedure (Fig. 1).
J. Perinat. Med. 2 (1974)
46 Giffei et al., First results and experiences with PDP-Program
PDP-List II
Non treatable factors or
factors of persisting risk after treatment
P. D.
1, General factors or fact
Age < 20 years and ^ years 30 1 1
Previous 1-2 infants^ 2500 g 2 2
or abortions ü>2. spontaneous) 2 2
Stillbirth . . . . .' 1
Neonatal death 1
Hight<160cm 1 1
Skeletal and pelvic anomal ies 1 1
Too f requent pregnancies (less f requent
than 1 year) 1
Low body weight before pregnancy « 55 kg) 1 1





a) in early pregnancy b) in late pregnancy . . 4 4(including (>28 week of gest.)
28. week of gest.)
3. Materna
a) independent of this pregnancy
Diabetes mellitus 1
Renal diseases 1
Endocrine disturbances (Ovarien insufficiency,
genital hypoplasia, menstrual cycle irregu-
farities, gonadotropin-treatment for steri-
lity, hyper- hypothyreodism, late concep-
tion >3 years involuntary) 2 2
Cardiac and pulmonal diseases 1
Multiple pregnancy 4 4
Non treatable risk factors score 1 1 1 1
Treatable or removable factors




Poor or inadäquate diet (e.g. < 50 g protein/day)
Smoking 1 - 5 cigarettes/day
6 - 20 cigarettes/day
resent pregnancy
Gestosis Age 20 - 29 ys.
(Toxemia) <20or30-34
^35
Cervical dilatation S external os: fingertip
or effacement 4 and/or cervix = 2 cm slight
l external os: finger
(when cervix sutured l and/or c. = 1 cm moderate
subtract 1 pt.) 1 external os: > finger




Malposition of fetus (breech, etc.)
Inadequate gain of weight or abdominal circumference
1 diseases
b) in present pregnancy
Urinary tract infections or asymptomatic bacteriuria
Acute infectious diseases
Other infections including syphilis, tuberculosis.
toxoplasmosis etc.
Virus infections incl. rubella, cytomegaly, Hepatitis
4. Environmental factors





Marital Status: single or divoced
Score: Treatable factors











































































































































































Fig. 1. PDP-list II for detection of potential risk of prematurity (P.) and dysmaturity (D.); I-para = patient exspecting
first child.
We realize that this System may require further
changes, äs the greater number of patients ob-
served according to this program will allow a
better evaluation of factor validity.
In addition, our list is mainly concerned with the
Situation in central Europe. Modifications will be
required for countries with different types of
population and socio-economic structures.
2.1 Results related to the degree of risk
The point System of PDP-list II was retrospec-
tively applied to PDP-list I in order to ascertain
the lowest number of points indicating real
danger. The results obtained in cooperation with
HÄUSSLER [cited in 13] are shown in Figs. 2 and 3.
The risk of prematurity rises sharply at 6
points. For that reason all patients with 6 or
more points are given special PDPrcare. Nearly
95% of all pregnant women with risk of pre-
maturity are thus covered.
The picture is not so clear for dysmaturity.
Patients with 6 or more points are also selected
for PDP^care. Thus we cover about 75% of
pregnancies with risk of dysmaturity.
If all pregnancies of both prematurity and dys-
maturity risk are included, about 40% of all
our pregnant women have to be monitored.
J. Perinat. Mcd. 2 (1974)
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% from all patients
0 Score up to 1 up to 2 up to 3
-1
20 88 166
n of patients (infants)
256 331 381 423 497 537
463 516 546
Fig. 2. 546 infants o£ 540 mothers checked by PDP-list
analysed under the aspect of prematurity risk. The upper-
most figures indicated by horizontal arrows show the
frequency (%) of prematurity in the particular point-group
in relation to all 546 cases checked. In the second row from
the top the frequency (%) of prematurity in the particular
point-group in relation to all underweight infants is shown.
The last row of figures within the columns shows the
percentage of pregnant women requiring special prenatal
care under this program in relation to the total number of
prenatal-care-patients. The curve at bottom right shows the
frequency (%) of prematurity in groups showing a certain
number of points.
2.2 Results related to a decrease in the rate
of low birth-weight newborns
Tab. I summarizes the results obtained in the
first two years of this program. At the Start the
additional expenditure (m inly in form of staff
Fig. 3. 546 infants of 540 mothers checked by PDP-list
analysed under the aspect of dysmaturity risk. See Fig. 2.
wages) required by the program was considerable,
enabling us to check only 30% of all patients
according to the PDP-list. The second year 50%
were checked.
It should be noted that we shall probably never
be able to include all patients in the PDP-program,
since about 30% are foreigners. A case history
has to be taken, and this is rarely possible with the
predominantly Turkish patients.
In reviewing our results, a comparison of Groups
II and III is of particular interest. The frequency of
newborns with a birth-weight of 2500 g or less
is 1.9% lower in the latter group. That would
indicate a 20% reduction of low birth-weight
infants. This result was an encouraging first
Tab. I
August 1971— July 1972
I. Total amount
II. Not checked by PDP-list
ΠΙ. By PDP-list checked and particularly managed if suspicious
August 1972— July 1973
I. Total ampunt
II. Not checked by PDP-list
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Tab. II
By PDP-list checked collective
August 1971— July 1972
Total amount
A. Suspicious and managed
B. Not suspicious (PDP-list I) and not particularly managed
C. Suspicious but patients neglected further consequences
August 1972— July 1973
Total amount
A. Suspicious and managed
B. Not suspicious (PDP-list II) and not particularly managed































success with the yet relatively inexact selection Thus during the initial consultation we perform a
list L vaginal examination and we repeat this every 2
The second year (Tab. I below) using PDP-list II, to 4 weeks, if not more f requently äs indicated
the incidence of newborns with low birth*·
weight was decreased by 3.6% in Group III äs
compared with Group II (p < 0.01), a reduc-
tion of more than 35% in the number of in-
fants with a birth-weight of 2500 g or less.
Tab. II shows the further differentiation of Group
III from Tab. I, providing the following inter-
(e. g. by increased uterine activity). A point
System is of value for recörding cervical finding
(Fig. 4). The early diägnosis of cervical incompe-
tency is possible and operative therapy f cervical
suturej can be applied.
Uterine contractions must be observed in this
manner so that when the cervix becomes shorter
esting results: Section B according to PDP-list I and/or the cervical canal opens, tocolytic therapy
(risk unsuspected) shows a still relatively high with beta-mimetic drugs can be performed.
incidence of 5.7% of low birth-weight infants.
The second year this figure was decreased to
1.6% using List II. This demonstrates the
value of the improved point System. The
3.1.1 Tocolytic therapy
We are successfülly using outpatient tocolytic
decrease from 5.7% to 1.6% is statistically sig- therapy at very early stages of increased
nificant (p < 0.005). uterine activity, äs we recommended in 1971 [12].
3. Practical procedures
 As SUggested by SCHWALM, cited by MOSLER [9],
The outpatient clinic for this special purpose is we consider more than 10 contractions, or more
organized differently than that for other patients. than 5 per day lasting longer than 40 seconds
Whenever possible the same physician attends to as pathological (increased) uterine activity and
the same patient thus ensuring continuity, better therefore as an indication for oral therapy with
super vision and treatment of individuals. beta-mimetic drugs. Unfortunätely there are
More time is required for such consultation, still no additional objective indications for
since the patient is questioned more intensively likewisely early therapy since there are no data on
and problems are explained to her more exactly. the borderline between the physiological and
Thus she can, for instance, determine increased pathological rate and durätion of contractions,
uterine activity herseif and record the frequency particularly in the everyday environment of the
and durätion of contractions. patient.
. We are using Th 1165a (Partusisten®; BOEH-
3.1 Special examinations and therapy
 RINGE^ ingelheim) combined if needed with
In addition, special examinations are performed Verapamil (Isoptin®; KNOLL AG). The latter
routinely at certain intervals. inhibits the side-eifects of Th 1165a on the
T. Perinat. Med. 2 (197
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Name:
Vag. examination for detection of cervical insufficiency




no : 3 cm
slight : 2 cm
moderate: 1 cm














































































































































































































Fig. 4. Point System for evaluating the cervical finding in respect to the risk of prematurity.
maternal heart ("palpitation"). Our tablets con-
tain 2.5 mg Th 1165a. The usual dose is 6 1/2
a tablet daily, taken at intervals of no more
than 4 hours. I£ necessary the dose may be
increased without risk to 6 tablets daily. (True
premature labor of course must be treated by
intravenous infusions of Th 1165 a.) WEI-
DIN GER et al. [17] give up to 6 5 mg daily,
which may, however, lower the subjective well-
beeing o£ the patient considerably.
One Isoptin retard dragee contains 120mg
Isoptin-hydrochloride. Depending on the dose
of Th 1165 a up to 3 dragees a day are admin-
istered.
Numerous data are available on the side-effects of
beta mimetic substances taken over prolonged
periods [11, 17]. Serious härm to mother or fetus
has not been noted.
3.1.2 Further important measures to prevent
premature labor
These include recommendation of work stop-
page or, if the risk is high, of bed rest.
In addiiion, the character of the risk factors has
many possible consequences. Exact descriptions
are not required here since it is well known that
e. g. gestosis (toxemia) or an infection during
pregnancy must be treated adequately.
3.1.3 Management of the risk of dysmaturity
In patients with dysmaturity risk, fetal growth
should be monitored with ultrasound. Determin-
ation of the biparietal head diameter alone is not
completely adequate. If, however, the transversal
thorax diameter is taken äs an additional measure
of the fetus, a more precise determination of
fetal size is obtained.
We use the nomogram published by HANSMANN
and VOIGT (Fig. 5, left top) which enables us to
estimate body-weight more accurately. According
to the author, the deviation f rom the actual weight
is less than 10% in 80% of all cases.
Fetal measurements are taken, depending on the
individual case, at 2 to 4 week intervals so that
an increasing deviation from the norm can
be seen in time.
The diagnosis of dysmaturity becomes more
probable if other findings confirm a nutritive
placental insufficiency.
J. Pcrinat. Med. 2 (1974)
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Fig. 5. Nomogram for ultrasonic determination of fetal size measuring biparietal head diameter and transversal
thorax diameter.
We use HPL s the main indicator. Urinary
estrogen determinations are used to a lesser
extent.
In order to diagnose the additional respiratory
insuf ficiency of the placenta f requently occurring
in later stages o£ pregnancy, amniocentesis or
amnioscopy together with cardiotocography
are perf ormed.
The most important therapeutic measure in
intrauterine malnutrition is bed rest.
All other measures, e. g. heparin therapy [l, 8],
tocolysis or other drug treatment to improve
uterine blood flow and supply of amino acids into
amniotic cavity s we have proposed [4, 14] have
not been tested sufficiently to recommend them
for routine clinical use.
4. Conclusion
Realisation of the PDP-program requires con-
siderable stafF and equipment expense. How-
ever, a clear decrease in the frequency of low
birth-weight infants has already been achieved
during the short time this program has been in
effect.
Summary
The majority of perinatal deaths and injuries occur in cases
of low birth-weight (2500 g and less). Hence obstetrical
and perinatal medicine is urgently pressed to decrease the
number of low birth-weight newborns.
We started our PDP-program in 1971. It is based on the
PDP-list filled in during the first consultation with the
pregnant woman and supplemented during further ex-
aminations.
The list contains 36 tisk factors separated into two factot
groups: non-treatable factors or factors of persisting
risk after treatment and treatable or removable factors.
J. Perinat. Med. 2 (1974)
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All risk factors are differentiated according to their signi-
ficance for pre- or dysmaturity.
The first year PDP-list I gave equal validity to all factors.
The second year, factors were weighed according to a
point System expressed in PDP-list II (Fig. 1).
From 6 points the prematurity risk and less distinctly
also the dysmaturity risk mcrease unequivocally (Figs.
2 and 3).
About 40% of all patients showed this number of points
and were supervised in a special prenatal-care clinic.
Tab. l summarizes results obtained in the first two years.
The first year (Tab. I above) only 30% of all pregnancies
could be checked using the PDP-list due to the expense of
additional staff, the second year we covered 50% (Tab. I
below).
In Group III there were 1.9% fewer low birth-weight
infants than in Group II which was not thus examined.
The second year this difference reached 3.6%. This
represents a total reduction in the number of infants
with low birth-weight by more than 35% (significant
for p < 0.01).
In Tab. II Group III of Tab. I is further differentiated.
The first year the incidence of 5.7% low birth-weight
infants in Section B (not at risk according to PDP-list I)
was still too high.
Using PDP-list II in the second year the percentage was
decreased to 1.6%. This decrease is significant for p < 0.005
and demonstrates the better selection due to the point
System of PDP-list II.
The PDP outpatient-care differs from other prenatal-care
äs follows:
1. Whenever possible, the patient is always examined
by the same doctor. This ensures better treatment and
a continuity in medical findings.
2. More time per patient for questioning, Information
and examinations usually not performed to such an
extent.
3. Vaginal examinations every 2 to 4 weeks, if not more
frequently äs indicated. Recording the cervical finding
(Fig. 4).
4. Outpatient tocolysis with beta-mimetic drugs at
very early stages of increased uterine activity; this
means: more than 10 contractions/day or more than
5/day lasting longer than 40 sec. Dosage: Partusisten®
(Th 1165a), 6 X 1.25 mg/day up to 6 X 2.5 mg/day,
combined if needed with Isoptin® retard (Verapamil),
depending on the extent of side-effects up to 3 X 120 mg/
day.
5. Control of fetal growth by ultrasound cephalo-thoraco-
metry every 2 to 4 weeks (Fig. 5). If the curve so
indicates, HPL determinations to diagnose nutritive
placental insufficiency.
6. In late pregnancy amnioscopy and cardiotocography
to determine respiratory placental insufficiency.
Realisation of the PDP-program requires considerable
staff and equipment. However, a clear decrease in the
frequency of low birth-weight newborns has already
been achieved during the short time the program has
been in efFect.
Keywords: Cephalo-thoraco-metry, dysmaturity, prematurity, prenatal-care, risk-list, tocolysis.
Zusammenfassung
Erste Erfahrungen und Ergebnisse mit unserem
Prämaturitäts- und Dysmaturitäts-Präventions-Pro-
gramm (PDP-Programm)
Der Hauptanteil der perinatal verstorbenen oder ge-
schädigten Kinder entstammt dem Kollektiv der Neuge-
borenen mit niedrigem Geburtsgewicht (< 2500 g). Es
ist daher eine vordringliche Aufgabe der Geburts- und
Perinatal-Medizin, die Zahl der untergewichtigen Kinder
zu senken. 1971 begannen wir mit der Anwendung unseres
PDP-Programmes. Das Kernstück ist die PDP-Liste, die
bei der ersten Beratung mit der Schwangeren ausgefüllt und
bei den weiteren Untersuchungen ergänzt wird. Die Liste
stellt einen Katalog von 36 Risikofaktoren dar, die gra-
phisch getrennt wurden in Faktoren mit nicht mehr ab-
stellbarer Belastung, die sogenannten „feststehenden
Faktoren" und in abstellbare oder behandelbare Fak-
toren, wobei auch hinsichtlich ihrer Bedeutung in Richtung
Prä- oder Dysmaturitäts-Gefährdung differenziert wird.
Im ersten Anwendungsjahr stellte die PDP-Liste I die
Faktoren noch gleichwertig nebeneinander. Im zweiten
Jahr wurde nach Auswertung der Ergebnisse der Versuch
gemacht, durch ein Punktesystem die einzelnen Fak-
toren auch in ihrer unterschiedlichen Wertigkeit
besser zu erfassen. Es entstand die PDP-Liste II (Fig. 1).
Ein eindeutiges Prämaturitätsrisiko besteht ab 6 Punkten
aufwärts (Fig. 2), ein Dysmaturitätsrisiko nicht ganz so
deutlich ebenfalls ab 6 Punkten (Fig. 3). Etwa 40% aller
Schwangeren erreichten bei uns diese Punktezahl und
wurden in einer eigens für sie eingerichteten Sprech-
stunde betreut. Die in den ersten beiden Jahren erzielten
Ergebnisse zeigt Tab. I. Im ersten Jahr (oberer Teil der
Tab. I) konnten wir wegen des zusätzlichen Aufwandes nur
knapp 30% aller Schwangeren mit der PDP-Liste erfassen.
In diesem Kollektiv III waren 1,9% weniger unterge-
wichtige Kinder zu verzeichnen als im nicht erfaßten
Kollektiv II. Im zweiten Jahr (unterer Teil der Tab. I)
betrug dieser Unterschied 3,6%. Das bedeutet eine Ge-
samtreduzierung der untergewichtigen Kinder um
mehr als 35% (statistisch signifikant mit p < 0,01).
In Tab. II ist das Kollektiv III der Tab. I weiter differen-
ziert. Im ersten Jahr war die Untergewichtigen-Rate in
Gruppe B (nach PDP-Liste I „nicht gefährdet") mit 5,7%
noch zu hoch. Durch den Einsatz der PDP-Liste II im
zweiten Jahr konnte die Rate der untergewichtigen
Kinder in Gruppe B auf 1,6% gesenkt werden. Der Ab-
fall ist mit p < 0,005 statistisch signifikant und beweist die
bessere Selektion durch das Punktesystem der Liste II.
J. Pcrinat. Mcd. 2 (1974) 4*
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Die PDP-Sprechstunde unterscheidet sich von den
anderen Klinik-Sprechstunden in folgenden Punkten:
1. Betreuung der Patientin von immer demselben
Kollegen; dadurch wird eine bessere Übersicht über den
Einzelfall und Kontinuität in den Untersuchungsbe-
funden gewährleistet.
2. Größerer Zeitaufwand pro Patientin für Aufklärung,
Befragung und Untersuchungen, die routinemäßig sonst
nicht in gleichem Umfange erfolgen können.
3. Vaginale Untersuchungen alle 2—4 Wochen, falls
nicht noch häufiger indiziert. Protokollierung des
Zervixbefundes (Fig. 4).
4. Einsatz der sehr frühzeitigen ambulanten Tokolyse
mit jß-Mimetika bei mehr als 10 Kontraktiorien/Tag
oder mehr als 5 Kontraktionen/Tag von mehr als
40 sec. Dauer. Dosierung: Partusisten® (Th 1165a)
6 1,25 mg bis 6 X 2,5 mg täglich (l Tab.. = 2,5 mg)
bei Bedarf in Kombination mit Isoptin® retard (Verapa-
mil) je nach Stärke der Nebenwirkungen bis 3 X 120 mg
täglich (l Drg. = 120 mg)..
 f
5. Kontrolle des fetalen Wachstums durch Kephalo-
Thorako-Metrie mit Ultraschall alle 2—4 Wochen
(Protokoll Fig. 5).
Bei verdächtigen Verläufen HPL-Bestimmungen zum
Erkennen einer nutritiven Plazentarinsuffizienz.
6. In der Spätschwarigerschaft Amnioskopie und Kar-
diotokographie zur Feststellung einer respiratorischen
Plazentarinsuffizienz.
Die Durchführung des PDP-Programmes erfordert einen
erheblichen personellen und apparativen Aufwand.
Doch schon unsere kurzen Erfahrungen zeigen, daß es
geeignet ist, die Rate der untergewichtigen Kinder
deutlich zu senken.
Schlüsselwörter: Dysmaturität, Kephalo-Thorako-Metrie, Prämaturität, Risikoliste, Schwangerenvorsorge, Tokolyse.
Resume
Premiers resultats et experiences de notre Programme
vde Prevention de Prematurite et de Dysmaturite
(Programme PDP)
La majorite des enfants morts ou souffrant de lesions en
periode perinatale figurent dans le groupe des nouveaux-nes
dont le poids ä la naissance est au-dessous de la norme
(< 2500 g). La medecine obstetrique et perinatale devra
donc s'efforcer de reduire le nombre des enfants de ce
groupe. C'est en 1971 que nous avons commence l'appli-
cation de notre Programme PDP centre sur la Liste PDP
qui est etablie a la premiere consultation de grossesse et
completee aux visites ulterieures. La Liste comporte un
catalogue de 36 facteurs de risque, divises graphiquement
en dits »facteurs fixes« (dont la charge n'est plus
corrigible) et en facteurs corrigibles ou traitables,
avec differenciation egalement selon leur degre d'importance
relatif au risque de prematurite ou de dysmaturite. La pre-
miere annee d'application, la Liste PDP I juxtaposait les
facteurs sans hierarchie des valeurs. La deuxieme annee et
apres evaluation des resultats, on a tente d'ordonner par
degre d'importance les divers facteurs selon un Systeme
de points: la Liste PDP II (Fig. 1).
Un risque precis prematurite existe ä partir de 6 points
et audessus (Fig. 2), un risque de dysmaturite ä partir
de 6 points (Fig. 3). Environ 40 pour cent des femmes
enceintes atteignirent chez nous ce nombre de points et
elles furent suivies dans une consultation speciale, in-
stituee a leur intention. Les resultats des deux premieres
annees figurent au Tab. I. La premiere annee (partie
super ieure de Tab. I) nous n'avons pu enregistrer que t out
juste 30 pour cent des femmes enceintes sur la Liste PDP ä
cause du travail supplementaire que cela demandait. On
compta dans ce Groupe III 1,9% de moins d'enfants avec
insuffisance de poids que dans le Groupe II non recense.
La deuxieme annee (partie inferieure du Tab. I), cette
difference atteignit 3,6%, ce qui represente une dimi-
nution globale des enfants de poids insuffisant superi-
eure ä 35% (statistiquement significatif avec p < 0,01).
Le Tab. II resume une differenciation plus detaillee et
precise du Groupe III du Tab. I. La premiere annee, le
pourcentage des enfants de poids insuffisant du Groupe B
(considere d'apres la Liste PDP I comme «non en danger»)
etait de 5,7%, soit encore trop eleve. Grace ä Tapplication
de la Liste PDP II la deuxieme annee, le pourcentage de
ces enfants du Groupe B a pu etre abaisse a 1,6%. La baisse
est, avec p < 0,005, statistiquement significative et prouve
Famelioration de la selection par le Systeme de points
de la Liste II.
La consultation PDP se distingue chez nous des autres
consultations de clinique par les diverses reglementations
suivantes:
1. Observation de la patiente toujours par le meine
medecin pour garantir un examen global meilleur et
plus continu de chaque cas particulier.
2. Temps plus long consacre a chaque patiente pour
la consultation et les examens qui, normalernent, ne
peuvent pas etre pratiques ä la meme echelie.
3. Examens vaginaux toutes les 2—4 semaines, ou
meme plus souvent si cela s'avere necessaire, avec
rapport du resultat cervical (Fig. 4).
4. Application de tocolyse ambulatoire avec j8-mime-
tiques en cas de plus de 10 contractions/jour ou de
plus de 5 contractions/jour d'une duree superieure ä 40 sec.
Dosage: Partusisten® (Th 1165a) 6 X 1,25 mg ä
6 X 2,5 mg par jour (l comprime = 2,5 mg), si ne-
cessaire en cornbinatiön avec Isoptin® retard (Vera-
pamil) selon l'acuite des effets secondaires ä 3 X 120 mg
par jour (l dragee = 120 mg).
5. Controle de la croissance foetale par cephalo-thoraco-
metrie avec ultrason toutes les 2—4 semaines (Fig. 5).
En cas de developpements suspects, determinations
HPL (Human Placental Lactogen) pour reconnaitre une
insuffisance placentäire nutritive.
6. En fin de grossesse, amnioscopie et cardiotocographie
pour depister une insuffisance placentäire respiratoire
eventuelle.
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